The F-box protein 22 (FBXO22), one of F-box proteins, has been identified to be critically involved in carcinogenesis. FBXO22 promotes proliferation in breast cancer and lung cancer, but suppresses migration and metastasis. FBXO22 exerts oncogenetic functions via promoting the ubiquitination and degradation of its substrates, including KDM4A, KDM4B, methylated p53, p21, KLF4, LKB1, Snail, CD147, Bach1, PTEN, and HDM2. FBXO22 is also regulated by several regulatory factors such as p53, miR-155, SNHG14, and circ_0006282. In this review, we summarize the regulatory factors and downstream targets of FBXO22 in cancers, discuss its functions in tumorigenesis, and further highlight the alteration of FBXO22 expression in a variety of human malignancies. Finally, we provide novel insights for future perspectives on targeting FBXO22 as a promising strategy for cancer therapy.

F-box 蛋白 22 (FBXO22) 是 F-box 蛋白之一，已被鉴定与癌发生密切相关。FBXO22 促进乳腺癌和肺癌的增殖，但抑制迁移和转移。FBXO22 通过促进其底物（包括 KDM4A、KDM4B、甲基化 p53、p21、KLF4、LKB1、Snail、CD147、Bach1、PTEN 和 HDM2）的泛素化和降解来发挥致癌功能。FBXO22 还受到多种调节因子的调节，例如 p53、miR-155、SNHG14 和 circ_0006282。在这篇综述中，我们总结了FBXO22在癌症中的调控因素和下游靶点，讨论了其在肿瘤发生中的功能，并进一步强调了FBXO22在多种人类恶性肿瘤中表达的变化。最后，我们为未来将 FBXO22 作为一种有前景的癌症治疗策略提供了新的见解。